Clinical trial
Phase 3 Study to Compare the Efficacy and Safety of Masitinib in Combination With Riluzole Versus Placebo in Combination With Riluzole in the Treatment of Patients Suffering From Amyotrophic Lateral Sclerosis (ALS)
NCT03127267 is registered in ClinicalTrials.gov with AB Science as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Phase 3 Study to Compare the Efficacy and Safety of Masitinib in Combination With Riluzole Versus Placebo in Combination With Riluzole in the Treatment of Patients Suffering From Amyotrophic Lateral Sclerosis (ALS)
- Lead sponsor
- AB Science
- Phase
- Phase 3
- Overall status
- Recruiting
- Start date
- February 2, 2021
- Completion date
- December 31, 2027
- Enrollment
- 495 (estimated)
- Sites
- 56
Conditions
As the registry lists them; a condition with its own page is linked.